Fig. 2From: Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinibRepresentative immunohistochemical images of ELTD1, CD34 and VEGFR2. Images demonstrating low ELTD1 (a), CD34 (b), VEGFR2 (c) and high ELTD1 (d), CD34 (e) and VEGFR2 (f) staining in the primary renal tumor vasculature in patients later treated for metastatic disease with sunitinib in the first or second line settingBack to article page